KAYFANDA 200 microgram hard capsules, KAYFANDA 400 microgram hard capsules, KAYFANDA 600 microgram hard capsules, KAYFANDA 1 200 microgram hard capsules
A4250-015
Phase 3 small_molecule active
Quick answer
KAYFANDA 200 microgram hard capsules, KAYFANDA 400 microgram hard capsules, KAYFANDA 600 microgram hard capsules, KAYFANDA 1 200 microgram hard capsules for Alagille Syndrome is a Phase 3 program (small_molecule) at Ipsen Pharma with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ipsen Pharma
- Indication
- Alagille Syndrome
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active